Targeting Chemoresistance in Small Cell Lung Cancer
Technical Report,01 Sep 2017,31 Aug 2019
Case Western Reserve University Cleveland United States
Pagination or Media Count:
Small cell lung cancer SCLC is the deadliest form of lung cancer and the most strongly associated with smoking history. Unfortunately, chemotherapy remains the main treatment option for patients with SCLC. Although this cancer typically responds extremely well, relapse is fast and largely inevitable. There are no effective therapies for relapsed tumors. The goal of our proposed study is to find new targets for drug therapy against relapsed SCLC tumors and provide continued hope for these patients. In this regard, we have identified a protein called HEPACAM2, which demonstrates unique, high expression in SCLC cell lines and tumors, making it a very attractive target. Knockdown of HEPACAM2 leads to cell cycle arrest, followed by apoptosis. Tankyrase 1 TNKS has been shown to polyADP-ribosylate HEPACAM2 and this modification is necessary for HEPACAM2 spindle localization and mitosis. Specific inhibitors of TNKS have been developed with little activity towards PARP1,a participant in the DNA damage response.
- Medicine and Medical Research